Neuromyelitis Optica Spectrum Disorder Inebilizumab Study in Children and Adolescents
What was tested
Treatment tested
- Inebilizumab
B-lymphocyte antigen CD19 binding agent
What it measured
Main measures
1. PK parameters, including maximum observed concentration (Cmax), area under the concentration-time curve from time 0 to 14 days post dose (AUC0-14d) and from time 0 extrapolated to infinity (AUC0-inf), systemic clearance, terminal elimination half-life (t½), and volume of distribution at steady state (Vss)
How the body handles the medicine
Other measures (1)
1. Disease activity endpoints include:
Loading reviews and guidelines…
Related trials
- Observational Safety Study in Women With Neuromyelitis Op…
Recruiting
Still running
- BEST-NMOSD
Phase 4 · Recruiting
Still running
- BETELGEUSE
Phase 1 · Not yet recruiting
Still running
- STARGlu-NMO
Phase 3 · Not yet recruiting
Still running
- Inectolizumab With Steroid Optimization in Newly Treated …
Not a drug-phase study · Not yet recruiting
Still running
- Safety and Efficacy of BAFF-R CART for Refractory Neuroim…
Phase 1 / Phase 2 · Recruiting
Still running
History
- In scope changed from true to false
Started
Mar 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error